Roche Group and Spark Therapeutics Gene Therapy Showing Promising Results
Looking for gene therapy treatments for chronic debilitating life-threatening diseases we fell on news from Spark Therapeutics, a member of the Roche Group (RHHBY); the firm announced preliminary data from part one of the ongoing Phase 1/2 open-label, non-randomized, dose-finding study of the investigational SPK-8016 . . .
This content is for paid subscribers.
Today’s Highlights February 5, 2021